Cargando…

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone

OBJECTIVE: To evaluate the long-term, real-life effects on non-motor symptoms (NMS) of opicapone compared to entacapone in levodopa-treated people with Parkinson’s disease (PwP). METHODS: A retrospective data analysis, with pre- and post-opicapone initiation data of 17 PwP with motor fluctuations co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leta, Valentina, van Wamelen, Daniel J., Aureli, Federico, Metta, Vinod, Trivedi, Dhaval, Cortelli, Pietro, Rodriguez-Blazquez, Carmen, Rizos, Alexandra, Ray Chaudhuri, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2023
Materias:	Neurology and Preclinical Neurological Studies - Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293442/ https://www.ncbi.nlm.nih.gov/pubmed/37036498 http://dx.doi.org/10.1007/s00702-023-02603-y

Ejemplares similares

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
por: Lau, Yue Hui, et al.
Publicado: (2022)

Apprends-moi l'art des petits pas: Levodopa, Carbidopa Intestinal Gel plus Entacapone
por: Jost, Wolfgang H.
Publicado: (2023)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa
por: LeWitt, Peter, et al.
Publicado: (2023)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: Rocha, José-Francisco, et al.
Publicado: (2021)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2021)

Viruses, parkinsonism and Parkinson’s disease: the past, present and future
por: Leta, Valentina, et al.
Publicado: (2022)

Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease
por: Jenner, P., et al.
Publicado: (2023)

Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone
por: Vokurka, Petr, et al.
Publicado: (2020)

Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?
por: Chaudhuri, K. Ray, et al.
Publicado: (2013)

Case report: Bilateral double beta peak activity is influenced by stimulation, levodopa concentrations, and motor tasks, in a Parkinson’s disease patient on chronic deep brain stimulation
por: Giannini, Giulia, et al.
Publicado: (2023)

Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
por: Tall, P., et al.
Publicado: (2023)

Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs
por: Mizuno, Yoshikuni, et al.
Publicado: (2017)

Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome
por: Grund, K. E., et al.
Publicado: (2023)

Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson’s disease
por: Müller, Thomas, et al.
Publicado: (2020)

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

The Gut Dysmotility Questionnaire for Parkinson's disease: Insights into development and pretest studies
por: Raeder, Vanessa, et al.
Publicado: (2023)

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Non-motor correlates of wrist-worn wearable sensor use in Parkinson’s disease: an exploratory analysis
por: van Wamelen, Daniel J., et al.
Publicado: (2019)

Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
por: Palacios, Natalia, et al.
Publicado: (2021)

A review of studies on gut microbiota and levodopa metabolism
por: Zhong, Zhe, et al.
Publicado: (2023)

Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
por: Rizos, A., et al.
Publicado: (2020)

Effects of Levodopa on Impairments to High-Level Vision in Parkinson's Disease
por: Anderson, Stephen, et al.
Publicado: (2020)

Use of Levodopa After a Stroke: A Systematic Review
por: Moncayo, Juan A, et al.
Publicado: (2022)

Evaluating Opicapone as Add-on Treatment to Levodopa/DDCI in Patients with Parkinson’s Disease
por: Jost, Wolfgang H
Publicado: (2022)

Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
por: Poulopoulos, Markos, et al.
Publicado: (2010)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
por: Öthman, Mezin, et al.
Publicado: (2021)

Differences in Levodopa Response for Progressive and Non-Progressive Micrographia in Parkinson's Disease
por: Zham, Poonam, et al.
Publicado: (2021)

Opioidergic Modulation of Striatal Circuits, Implications in Parkinson's Disease and Levodopa Induced Dyskinesia
por: Sgroi, Stefania, et al.
Publicado: (2018)

The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience
por: Băjenaru, O., et al.
Publicado: (2015)

Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Wang, Libo, et al.
Publicado: (2018)

Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson's disease
por: Diaconu, Ştefania, et al.
Publicado: (2023)

Case report: Levodopa-responsive parkinsonism with akinetic mutism after ventriculo-peritoneal shunt
por: Zhang, Ying, et al.
Publicado: (2023)

Levodopa-Responsive Parkinsonian Syndrome Secondary to a Compressive Craniopharyngioma: A Case Report
por: Rodriguez, Wilson, et al.
Publicado: (2023)

Chaudhuri’s Dashboard of Vitals in Parkinson’s syndrome: an unmet need underpinned by real life clinical tests
por: Qamar, Mubasher A., et al.
Publicado: (2023)

Sensitization and Interoception as Key Neurological Concepts in Osteopathy and Other Manual Medicines
por: D'Alessandro, Giandomenico, et al.
Publicado: (2016)

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
por: Brooks, David J
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_mfq0ts1ng31vj9l0s7pk0r9qoj